Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
intravenous |
| gptkbp:category |
anticancer agents
molecular chaperone inhibitors |
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
Phase II Phase III |
| gptkbp:developedBy |
pharmaceutical companies
|
| gptkbp:discoveredIn |
1990s
|
| gptkbp:effect |
disrupt protein folding
induce apoptosis in cancer cells |
| gptkbp:example |
gptkb:17-AAG
gptkb:geldanamycin ganetespib luminespib onalespib |
| https://www.w3.org/2000/01/rdf-schema#label |
HSP90 inhibitors
|
| gptkbp:investigatedBy |
gptkb:cancer
leukemia multiple myeloma prostate cancer |
| gptkbp:mechanismOfAction |
inhibit heat shock protein 90
|
| gptkbp:sideEffect |
fatigue
ocular toxicity gastrointestinal toxicity hepatic toxicity |
| gptkbp:target |
HSP90 protein
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:14q32.33_(HSP90AA1)
gptkb:HSP90AA1 gptkb:HSP90AB1 |
| gptkbp:bfsLayer |
8
|